SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)

Plain-language summary

This study collects patient data to search for disease-related biomarkers in cerebral amyloid angiopathy. It enrolls patients aged 55 and older who have a possible, probable, or definite diagnosis of cerebral amyloid angiopathy according to the Boston criteria and have had at least one brain MRI. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Intervention

CAA patients data collection

Start date

6/1/2020

Estimated completion

11/1/2027

Countries

Italy

Related genes

Locations

• Milan, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All consecutive patients ≥55 years (with the exception of genetic cases), referred to the participating centres, with a diagnosis of possible probable and definite symptomatic or asymptomatic CAA, defined according to the modified Boston neuroradiological criteria, who had undergone at least one brain MRI (mandatory requirement for inclusion of the patient in the study) will be recruited.

Exclusion Criteria:

* evidence of other causes of cerebral hemorrhage (brain tumors, arteriovenous malformations, aneurysms, cavernous angiomas), contraindications to brain MRI, pregnancy and breastfeeding